MLNT Insider Trading Activity and SEC Form 4 Filings
MLNT insider trading summary
No open-market insider purchases or sales of Melinta Therapeutics, Inc. (MLNT) have been reported on SEC Form 4 in the past 12 months.
Latest MLNT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 27, 2019 | John Johnson | Chief Executive Officer | Sell | $72K (13,000 @ $5.57) |
| May 29, 2018 | Vatera Healthcare Partners LLC | Director | Buy | $37.5M (7,500,000 @ $5.00) |
| May 29, 2018 | Vatera Holdings LLC | Director | Buy | $37.5M (7,500,000 @ $5.00) |
| May 29, 2018 | Vatera Healthcare Partners LLC | Director | Buy | $39.4M (7,878,500 @ $5.00) |
| May 29, 2018 | Kevin Ferro | Director | Buy | $39.4M (7,878,500 @ $5.00) |
| May 29, 2018 | Vatera Holdings LLC | Director | Buy | $39.4M (7,878,500 @ $5.00) |
| May 29, 2018 | Kevin Ferro | Director | Buy | $37.5M (7,500,000 @ $5.00) |
| May 29, 2018 | David Zaccardelli | Director | Buy | $200K (40,000 @ $5.00) |
| May 29, 2018 | Erin Duffy | Chief Scientific Officer | Buy | $20K (4,000 @ $5.00) |
| May 29, 2018 | Sue Cammarata | Chief Medical Officer | Buy | $20K (4,000 @ $5.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.